Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome With Diarrhea

Interventions

DRUG: BEKINDA
DRUG: Placebo

Sponsor

RedHill Biopharma Limited